These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33101763)

  • 21. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice.
    Alicino I; Giglio M; Manca F; Bruno F; Puntillo F
    Pain; 2012 Jan; 153(1):245-249. PubMed ID: 22082570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.
    McDowell GC; Pope JE
    Neuromodulation; 2016 Jul; 19(5):522-32. PubMed ID: 26856969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Considerations and methodology for trialing ziconotide.
    Burton AW; Deer TR; Wallace MS; Rauck RL; Grigsby E
    Pain Physician; 2010; 13(1):23-33. PubMed ID: 20119460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neuropsychiatric side effects of intrathecal ziconotide].
    Ayuga-Loro F; Brocalero-Camacho Á; Quintas-López MV; Cabrera-Feria JR
    Rev Neurol; 2011 Jan; 52(1):61-3. PubMed ID: 21246497
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain.
    Wallace MS; Kosek PS; Staats P; Fisher R; Schultz DM; Leong M
    Pain Med; 2008 Apr; 9(3):271-81. PubMed ID: 18366507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using ziconotide for intrathecal infusions.
    Mitchell AA; Sapienza-Crawford AJ; Hanley KL; Lokey KJ; Wells L
    Nursing; 2008 Dec; 38(12):19. PubMed ID: 19033968
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute rhabdomyolysis in a patient with long-term exposure to intrathecal ziconotide: a case report.
    Horazeck C; Huh AS; Huh BK
    Pain Pract; 2015 Mar; 15(3):E34-9. PubMed ID: 25565390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term intrathecal ziconotide for chronic pain: an open-label study.
    Webster LR; Fisher R; Charapata S; Wallace MS
    J Pain Symptom Manage; 2009 Mar; 37(3):363-72. PubMed ID: 18715748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.
    Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M
    Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute cardiovascular toxicity of low-dose intrathecal ziconotide.
    Heifets BD; Smith SM; Leong MS
    Pain Med; 2013 Nov; 14(11):1807-9. PubMed ID: 23855951
    [No Abstract]   [Full Text] [Related]  

  • 31. Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options.
    Deer TR; Pope JE; Hanes MC; McDowell GC
    Pain Med; 2019 Apr; 20(4):784-798. PubMed ID: 30137539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experience in treatment of patients with neuropathic facial pain using ziconotide].
    Lux EA; Rasche D
    Schmerz; 2011 Aug; 25(4):434-9. PubMed ID: 21818721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain.
    Wermeling DP; Berger JR
    Pharmacotherapy; 2006 Mar; 26(3):395-402. PubMed ID: 16503720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature.
    Webster LR
    Pain Med; 2015 Jul; 16(7):1265-77. PubMed ID: 25645109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of First-Line Ziconotide Intrathecal Drug Therapy for Neuropathic Pain on Disability, Emotional Well-Being, and Pain Catastrophizing.
    Shao MM; Khazen O; Hellman A; Czerwinski M; Dentinger R; DiMarzio M; Gillogly M; Hadanny A; Argoff C; Pilitsis JG
    World Neurosurg; 2021 Jan; 145():e340-e347. PubMed ID: 33096281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ziconotide: an update and review.
    Williams JA; Day M; Heavner JE
    Expert Opin Pharmacother; 2008 Jun; 9(9):1575-83. PubMed ID: 18518786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased risk of suicide under intrathecal ziconotide treatment? - a warning.
    Maier C; Gockel HH; Gruhn K; Krumova EK; Edel MA
    Pain; 2011 Jan; 152(1):235-237. PubMed ID: 21041028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ziconitide.
    Greenberg EN
    J Pain Palliat Care Pharmacother; 2011; 25(4):380-1. PubMed ID: 22126177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ziconotide Combination Intrathecal Therapy for Noncancer Pain Is Limited Secondary to Delayed Adverse Effects: A Case Series With a 24-Month Follow-Up.
    Hayek SM; Hanes MC; Wang C; Veizi IE
    Neuromodulation; 2015 Jul; 18(5):397-403. PubMed ID: 25655991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ziconotide: an innovative alternative for intense chronic neuropathic pain].
    Valía-Vera JC; Villanueva VL; Asensio-Samper JM; López-Alarcón MD; de Andrés JA
    Rev Neurol; 2007 Dec 1-15; 45(11):665-9. PubMed ID: 18050098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.